Testing Two Drugs for Adult-Onset Still's Disease
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether two injectable medicines (goflikicept and olokizumab) work safely as a second treatment for adults with Still's disease, a rare inflammatory condition. If you've already tried one treatment without enough improvement, this trial may help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Adult-Onset Still's Disease (AOSD)
- Your disease is active or has low disease activity right now
- If you take corticosteroids, your dose must be stable for 2+ weeks (max 60 mg/day prednisolone equivalent)
- If you take methotrexate, your dose must be stable for 4+ weeks (max 30 mg/week)
- You can visit the clinic regularly, receive injections, and follow study instructions
- You agree to use effective birth control for at least 8 weeks after your last study injection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with adult-onset Still's disease or similar autoinflammatory conditions to learn more about these illnesses over time. By participating, you can help doctors better understand and treat these conditions.
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
This trial tests a new drug called firsekibart against an existing drug, anakinra, for people with active adult-onset Still's disease. It aims to see if firsekibart is more effective in controlling symptoms like fever, joint pain, and rash.
This trial tests a new drug called MAS825 for people with Still's disease that is still active despite other treatments. It aims to see if the drug can reduce symptoms like fever, rash, joint pain, or a serious complication called macrophage activation syndrome.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study follows people with systemic juvenile idiopathic arthritis (sJIA), adult-onset Still’s disease (AOSD), and similar conditions to learn how the illness works over time. It also collects blood and family information to study genetics and explain what causes flare-ups, which may help future care.
Hear when a new Still Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.